In this nationwide retrospective study, we analysed early acquisition of Achromobacter spp. in Danish cystic fibrosis (CF) patients from 2000 to 2011, excluding cross-infections. Methods: Thirty-four primary isolates were identified by partial sequencing of recA, tyrB and icd, and were subjected to extended antimicrobial susceptibility testing. Achromobacter xylosoxidans accounted for 13 (38%) of the isolates, and an unnamed species, tentatively designated MLSA cluster III, accounted for 11 (32%) of the isolates. Antimicrobial susceptibility testing showed that meropenem, piperacillintazobactam and trimethoprim/sulfamethoxazole were highly active against chemotherapy-naïve Achromobacter, while ceftazidime, colistin and tobramycin were judged to have adequate activity for inhalation therapy. We assessed effectiveness of early antimicrobial treatment by a Kaplan-Meier estimation of time to recurrence of Achromobacter spp. A significant difference was observed between 25 patients treated with inhaled ceftazidime, colistin, or tobramycin, and 22 patients who did not receive inhaled antibiotics: three years after primary acquisition, 55% of treated patients remained free of Achromobacter spp., in contrast to 17% of untreated patients. Conclusion: Our findings suggest that early treatment with inhaled antibiotics may prevent or postpone chronic infection with Achromobacter species in CF patients. Objectives: Pseudomonas aeruginosa pulmonary infection is a main cause of illness and death for patients with cystic fibrosis. P. aeruginosa is also intrinsically resistant to many antimicrobial agents. This resistance has been attributed to its efflux capabilities, its impermeable outer membrane, its tendency to colonize surfaces as a biofilm, and its ability to acquire and maintain antibiotic resistance-encoding plasmids. There is pressing demands for novel strategies for targeting infections in cystic fibrosis lung patients. Recent studies by our group have shown the effectiveness of a liposomal tobramycin-bismuth (lipo Tob-Bi) formulation to eradicate P. aeruginosa. However, preliminary studies have shown that concentrations of free Tob-Bi inhibit lung cell growth and exhibit cytotoxicity. Methods: Using different approaches like light microscopy (cell morphology), cell titer blue and protein assays (cell viability), DAPI staining and fluorescence microscopy (DNA damage), autometallography (bismuth deposition) and flow cytometry (effect on cell growth) in A549 cell lines. A reduction of cell growth, an increased bismuth deposition, and DNA damage in presence of free Tob-Bi compared to the liposomal formulation.
Objectives: Aztreonam lysine for inhalation (AZLI) has been proven effective in the treatment of chronic Ps. aeruginosa (PA) infection in CF. It is not clear whether patients with other infecting organisms, such as B. cepacia complex (Bcc), could benefit from this treatment. We aim to investigate the clinical efficacy of AZLI for Bcc in CF. Methods: We reviewed medical files of 4 patients infected with B. multivorans who were treated with AZLI. Bcc prevalence in Belgium is 2%. Results: The patients were 26 (A, male, severe liver disease and portal hypertension), 33 (B female), 14 (C, female, CFRD) and 12 (D, male) years old. A was infected for several years, whereas B, C and D were newly acquired colonisations. A and B had co-infection with PA. A, B and C were treated for 48 weeks with AZLI (28 day on/off cycle) as add-on therapy to another cyclical inhaled antibiotic, D for 12 weeks continuously as mono-inhaled therapy. In addition, A received 3-monthly courses of IV antibiotics; B, C and D had 1 IV course at time of acquisition. Mean lung function values remained stable for 48 weeks during AZLI. D showed a slight improvement in FEV1 of 4% after 12 weeks. A did not deteriorate further. In B and D, Bcc was not found in the respiratory cultures during AZLI inhalation. However in D, Bcc reappeared after AZLI was stopped. B and C had less pulmonary exacerbations after start of AZLI. No adverse effects were seen. Conclusion: These Bcc-infected patients seem to benefit from a treatment with AZLI. In 2 recent acquisitions, eradication of B. multivorans was seen. AZLI was well tolerated, also in young patients. Clinical trials studying the efficacy of AZLI for Bcc are ongoing. Objectives: Ceftazidime (CAZ) remains one of the main anti-infective agents against P. aeruginosa in cystic fibrosis patients. Caregivers reported various disturbing phenomena of intolerance, especially in case of prolonged infusion. A spontaneous production of pyridine (P), which is a toxic product, raises some concern. Our aim was to study the kinetics of spontaneous degradation of CAZ shaped in Portable Infusion Pumps (PIPs) and the potential risk of exposure to P. Methods: 18 PIPs LV10 Baxter ® were filled by 12g of CAZ diluted in 230 mL of saline solution (52.17 mg/mL). Devices were stored either at 4, 22, or 33ºC. Samples were collected immediately before and then every 4 hrs after the shaping of PIPs until the 24 th h. Both CAZ and P were analysed by HPLC. Model-independent kinetic parameters were determined for both CAZ and P (Table 1) .
Results: See Table 1 . 
